Last checked at 10 Feb 2023 14:01
Renalytix plc
("Renalytix" or the "Company")
Director/PDMR Dealing
LONDON and SALT LAKE CITY, February 10, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) confirms that further to the announcement on February 8 of a c.$20.3 million private placement, the Company has been informed that certain investment vehicles connected with Christopher Mills, Non-Executive Chairman, have completed the purchase of 346,375 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.90 per Ordinary Share.
Following completion of this purchase, Christopher Mills and the investment vehicles connected with him are interested in 10,072,500 Ordinary Shares representing 10.8% of the issued share capital of the Company as enlarged by the recent private placement.
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea | ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | |
About Kidney Disease
Kidney disease is a public health epidemic affecting over 850 million people globally.1 The Centers for Disease Control and Prevention estimates that 15% of U.S. adults, or approximately 37 million people2, have chronic kidney disease (CKD). Nearly 95% of people with CKD are in early stages 1-33. Despite its magnitude, early-stage (1-3) CKD is underdiagnosed and undertreated, largely because it's asymptomatic at this time in the disease. As many as 9 in 10 adults with CKD, and about 2 in 5 adults with severe CKD do not know they have the condition.3
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
About KidneyIntelX™
KidneyIntelX™ is a laboratory developed test demonstrated to be a reliable, bioprognostic™ methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and Renalytix has submitted for De Novo marketing authorization. To learn more about KidneyIntelX and review the evidence, visit www.kidneyintelx.com.
Sources
1 https://www.theisn.org/blog/2020/11/27/more-than-850-million-worldwide-have-some-form-of-kidney-disease-help-raise-awareness/2 https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html3 https://www.cdc.gov/kidneydisease/basics.html
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
|
Harwood Capital LLP* | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Christopher Mills, Non-Executive Chairman, is Chief Investment Officer of Harwood | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Renalytix plc | |||
b)
| LEI
| 213800NTOH3FK3WER551 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of £0.0025 each | |||
Identification code | GB00BYWL4Y04
| ||||
b)
| Nature of the transaction
| Subscription for New Ordinary Shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
£0.90 | 346,375 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | 346,375 | ||||
- Price | £0.90 | ||||
e)
| Date of the transaction
| 8 February 2023 | |||
f)
| Place of the transaction
| Off market | |||
*Christopher Mills is partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher's shareholding is made up of ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC, Oryx International Growth Fund Limited and Harwood Capital LLP.